Last reviewed · How we verify
prophylactic Valganciclovir
prophylactic Valganciclovir is a Nucleoside analog antiviral Small molecule drug developed by Rabin Medical Center. It is currently FDA-approved for Prophylaxis of cytomegalovirus (CMV) disease in high-risk immunocompromised patients (e.g., transplant recipients). Also known as: Valcyte.
Valganciclovir is a prodrug of ganciclovir that inhibits viral DNA polymerase to prevent cytomegalovirus (CMV) replication in immunocompromised patients.
Valganciclovir is a prodrug of ganciclovir that inhibits viral DNA polymerase to prevent cytomegalovirus (CMV) replication in immunocompromised patients. Used for Prophylaxis of cytomegalovirus (CMV) disease in high-risk immunocompromised patients (e.g., transplant recipients).
At a glance
| Generic name | prophylactic Valganciclovir |
|---|---|
| Also known as | Valcyte |
| Sponsor | Rabin Medical Center |
| Drug class | Nucleoside analog antiviral |
| Target | CMV DNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Valganciclovir is rapidly converted to ganciclovir in the body, which then selectively inhibits CMV DNA polymerase by competing with deoxyguanosine triphosphate. This prevents viral DNA synthesis and replication. When used prophylactically, it reduces the risk of CMV disease in high-risk immunocompromised populations such as transplant recipients.
Approved indications
- Prophylaxis of cytomegalovirus (CMV) disease in high-risk immunocompromised patients (e.g., transplant recipients)
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Diarrhea
- Nausea
- Headache
- Renal impairment
Key clinical trials
- Effectiveness of an Immune-guided Cytomegalovirus Infection Preventive Strategy Compared to a Universal Prophylactic Strategy in Renal Transplant Patients (PHASE3)
- Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study (NA)
- Use of Tacrolimus and MTOR Inhibitors With Anticipatory Therapy vs. Tacrolimus and Mycophenolic Acid With Universal Prophylaxis in Renal Recipients at High Risk of Posttransplant Cytomegalovirus. (PHASE4)
- Cell-mediated Immunity for Prevention of CMV Disease (NA)
- Randomized Clinical Trial, Open, Multicenter Parallel, no Suspension Inferiority Prophylactic Treatment With Valganciclovir in Kidney Transplant CMV-seropositive Cellular Immunity to Develop CD8 + CMV-specific Treatment After Induction Thymoglobulin. (PHASE3)
- Multicenter Clinical Trial to Evaluate the Efficacy of a Preventive Strategy Against CMV Infection in Heart Transplant Patients, Based on the Specific T Cells Response (PHASE4)
- Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients (PHASE4)
- Study of Prophylactic Vs Preemptive Valganciclovir (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- prophylactic Valganciclovir CI brief — competitive landscape report
- prophylactic Valganciclovir updates RSS · CI watch RSS
- Rabin Medical Center portfolio CI
Frequently asked questions about prophylactic Valganciclovir
What is prophylactic Valganciclovir?
How does prophylactic Valganciclovir work?
What is prophylactic Valganciclovir used for?
Who makes prophylactic Valganciclovir?
Is prophylactic Valganciclovir also known as anything else?
What drug class is prophylactic Valganciclovir in?
What development phase is prophylactic Valganciclovir in?
What are the side effects of prophylactic Valganciclovir?
What does prophylactic Valganciclovir target?
Related
- Drug class: All Nucleoside analog antiviral drugs
- Target: All drugs targeting CMV DNA polymerase
- Manufacturer: Rabin Medical Center — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for Prophylaxis of cytomegalovirus (CMV) disease in high-risk immunocompromised patients (e.g., transplant recipients)
- Also known as: Valcyte
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing